Company: Sun Pharmaceutical Industries Ltd.

Shares of Sun Pharmaceutical Industries rallied 3% after the company received a rare double upgrade from global research house Morgan Stanley.
July 15, 2019, 1:21 p.m.

Ezallor Sprinkle is formulated as extended-release-coated pellets that may be sprinkled over soft food such as applesauce, can be swallowed whole, or administered via a nasogastric tube to facilitate long-term, once-daily administration.
July 15, 2019, 12:11 p.m.

Sun Pharma on Monday announced the launch of Ezallor Sprinkle capsules, used for treatment of elevated lipid disorders in people who have difficulty
July 15, 2019, 11:01 a.m.

Ezallor Sprinkle (rosuvastatin) capsules is indicated for three types of lipid disorders in conjunction with diet in adults
July 15, 2019, 10:50 a.m.

Sun Pharma jumped 6% and among top gainers in the pharma index, followed by shares of Piramal Ent, Glenmark and Aurobindo Pharma, which rose in the range of 3-4% respectively, were also among top contributors.
July 9, 2019, 12:46 p.m.

SCO-088 is a novel and highly selective Bcr Abl kinase inhibitor intended for the treatment of resistant Chronic Myelogenous Leukemia. SCO-088 is a potent inhibitor of Bcr-Abl and its mutant forms.
July 8, 2019, 11:42 a.m.

Under terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential.
June 27, 2019, 3:06 p.m.

Check out the companies which will be in focus during trade today based on recent and latest news developments.
June 20, 2019, 7:44 a.m.

The interim analysis revealed that over 71% of patients treated with ILUMYA experienced a 20% improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study.
June 14, 2019, 12:53 p.m.

Caught up in a corporate governance controversy, an insider view shows Sun trod ethical grey zones since the 1990s
May 29, 2019, 10:36 p.m.